Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
— Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform — Financing led by Goldman Sachs Alternatives with participation by new and existing investors FREMONT, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Attovia Therapeutics today announced the closing of a $105 million oversubscribed Series […]
